English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: Pregnancy is a special physiological condition where the treatment needs a special concern. Moreover, pharmacotherapy during pregnancy is very challenging since only a few medicines have been specifically tested for safety. Objective: The aim of this study was to evaluate the utilization pattern and the teratogenicity risk of the drugs prescribed to pregnant women in Fiche Hospital, Ethiopia. Methods: A retrospective study was conducted by reviewing medical case files of 323 pregnant women, encountered with at least one drug, out of 1876 pregnant women attending antenatal clinic from February 09/2013 to March 09/2014. The prescription pattern was assessed from perspectives of World Health Organization (WHO) core drug use indicators, and the United States Food and Drug Administration (FDA) fetal harm classification. Results: Among 1876 pregnant women who visited ANC clinic, a total of 323 women received 456 medications. The age of the patients was within the range of 16-49 years and the majority of them (77.22%) were within the age group of 20-35 years. The majority of pregnant women (80.47%) visited antenatal care (ANC) during their first trimester gestation. Out of the total drugs prescribed, category A drugs comprised 20.83%, category B (26.34%), category C (24.34%), category C/D (9.65%), category D (9.43%) and category X (1.09%). Percentage of encounter with antibiotics and injectable drugs were 31.8% and 19.30%, respectively. Conclusion: Approximately half of the pregnant women utilized drugs from FDA category C, D and X which are thought to cause fetal harm; therefore, the use of these drugs should be minimized.

Drug Utilization Pattern and Potential Teratogenicity Risk among Pregnant Women Visiting Antenatal Clinic: The Case of a Primary Hospital